⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756793 | 0.78 | — | — | |
| SCHEMBL8673647 | 0.75 | ALDH1A1 (0.39) | — | |
| SCHEMBL117701 | 0.73 | — | — | |
| SCHEMBL11618547 | 0.72 | ALDH1A1 (0.33) | — | |
| SCHEMBL7117503 | 0.72 | — | — | |
| SCHEMBL350921 | 0.71 | — | — | |
| SCHEMBL6035485 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL22578564 | 0.71 | — | — | |
| SCHEMBL17499016 | 0.71 | — | — | |
| SCHEMBL555029 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115655-A1 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION | ASTRAZENECA PHARMACEUTICALS LP | 2023-04-13 | — | — | US | disclosed |
| US-11535659-B2 | Engineered polypeptides having enhanced duration of action | AMRYT PHARMACEUTICALS INC. (US) | 2022-12-27 | — | — | US | disclosed |
| EP-3241558-B1 | HIGHLY SOLUBLE LEPTINS | AEGERION PHARMACEUTICALS INC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200362006-A1 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION | AMRYT RESEARCH LIMITED (IE) | 2020-11-19 | — | — | US | disclosed |
| US-20200276135-A1 | Dosage Forms and Related Therapies | PHILERA NEW ZEALAND LIMITED (NZ) | 2020-09-03 | — | — | US | disclosed |
| US-10543178-B2 | Dosage forms and related therapies | PHILERA NEW ZEALAND LIMITED (NZ) | 2020-01-28 | — | — | US | disclosed |
| EP-2729160-B1 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION AND REDUCED IMMUNOGENICITY | AEGERION PHARMACEUTICALS INC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20190000778-A1 | Dosage Forms and Related Therapies | PHILERA NEW ZEALAND LIMITED (NZ) | 2019-01-03 | — | — | US | disclosed |
| US-20180344813-A1 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION WITH REDUCED IMMUNOGENICITY | AMYLIN PHARMACEUTICALS, LLC | 2018-12-06 | — | — | US | disclosed |
| US-20180305430-A1 | Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity | AEGERION PHARMACEUTICALS, INC. | 2018-10-25 | — | — | US | disclosed |
| WO-2004037168-A2 | TREATMENT OF PANCREATITIS WITH AMYLIN | AMYLIN PHARMACEUTICALS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004017956-A1 | DOSAGE FORMS AND RELATED THERAPIES | PROTEMIX CORPORATION LIMITED (NZ) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003101395-A2 | FORMULATIONS FOR AMYLIN AGONIST PEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030092606-A1 | Formulations for amylin agonist peptides | ASTRAZENECA PHARMACEUTICALS LP | 2003-05-15 | — | — | US | disclosed |
| US-6410511-B1 | — | — | 2002-06-25 | — | — | US | disclosed |
| US-6410511-B2 | LIQUID, OF AMYLIN AGONIST SUCH AS PRAMLINTIDE, A CARBOHYDRATE OR POLYHYDRIC ALCOHOL, AND AN ACETATE, PHOSPHATE, CITRATE, OR GLUTAMATE BUFFER, ACIDIC PH; INJECTABLE; STORAGE STABILITY | AMYLIN PHARMACEUTICALS, INC. | 2002-06-25 | — | — | US | disclosed |
| US-20010043934-A1 | FORMULATIONS FOR AMYLIN AGONIST PEPTIDES | ASTRAZENECA PHARMACEUTICALS LP | 2001-11-22 | — | — | US | disclosed |
| EP-1044015-A4 | FORMULATIONS FOR AMYLIN AGONIST PEPTIDES | AMYLIN PHARMACEUTICALS INC (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1044015-A1 | FORMULATIONS FOR AMYLIN AGONIST PEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999034822-A1 | FORMULATIONS FOR AMYLIN AGONIST PEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-07-15 | — | — | WO | disclosed |